Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2004-03-12
2010-06-15
Bristol, Lynn (Department: 1643)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C424S146100
Reexamination Certificate
active
07736646
ABSTRACT:
Novel methods of inhibiting angiogenesis or tumorigenesis with compositions that inhibit the apelin/APJ signaling pathway are provided. Also provided are methods of promoting angiogenesis or tumorigenesis with compositions comprising an apelin polypeptide or small molecule agonist. The present invention further provides methods for identifying therapeutic agents that affect angiogenesis.
REFERENCES:
patent: 6492324 (2002-12-01), Hinuma et al.
patent: 2003/0092618 (2003-05-01), Hinuma et al.
patent: 2004/0033495 (2004-02-01), Murray et al.
patent: 2006/0159676 (2006-07-01), Krieg
patent: 2010/0028256 (2010-02-01), St. Croix et al.
patent: WO00/68224 (2000-11-01), None
Jain (Scientific American Jul. 1994).
Chatterjee et al (Cancer Immunol. Imunother., 1994.
Dermer (Biotechnology 12: 320, 1994).
Gura et al (Science vol. 278 Nov. 1997 1041-1042).
Traschel et al. (Adv. Drug Delivery Rev. 58:735-754 (2006)).
Seaver (1994; Genetic Engineering vol. 14(14):pp. 10 and 21).
Burgess et al, (Journal of Cell Biology 111:2129-2138 (1990)).
Lazar et al (Molecular and Cellular Biology 8:1247-1252 (1988)).
Schwartz et al, (Proc Natl Acad Sci USA 84:6408-6411 (1987)).
Lin et al (Biochemistry USA 14:1559-1563 (1975)).
Stein (Pharmacology and Therapeutics 85: 231-236 (2000).
Stein (J. Clinical Investigation 108(5): 641-644 (2001).
Caplen, Gene Therapy 11(16): 1241-1248 ( 2004).
Chirila et al, Biomaterials 23:321-342 (2002).
Gerwirtz et al., Blood 92(3): 712-736 (1998).
Jen et al., Stem Cells 18: 307-319 (2000).
Opalinska et al., Nature Reviews 1:503-514 (2002).
Scherer et al., Nature Biotechnology 21(12), pp. 1457-1465 (2003).
Kurreck et al., Current Opinion Drug Discovery and Development 7(2): 179-187 (2004).
Lu et al., RNA Interference Technology, Cambridge, Appasani, ed., 2005, p. 303.
Samarsky et al., RNA Interference Technology, Cambridge, Appasani, ed., 2005, pp. 389-394.
Sioud, RNA Silencing, Methods and Protocols, Humana Press, 2005.
Simeoni et al., RNA Silencing, Methods and Protocols, Humana Press, 2005, p. 251.
Mahato et al., Expert Opinion on Drug Delivery, Jan. 2005, vol. 2, No. 1, pp. 3-28.
Felmeden et al., Eur. Heart J. 24:586-603 (2003).
Voskoglou-Nomikos (Clin. Can. Res. 9:4227-4239 (2003)).
Dennis (Nature 442:739-741 (2006)).
Cespdes et al. (Clin. Transl. Oncol. 8(5):318-329 (2006)).
Kleinz et al. Regul. Peptides 118:119-125 (2004).
Fujimori et al. (J. Nuc. Med. 31:1191-1198 (1990)).
Beckman et al. (Can. 109:170-179 (2007)).
Thurber et al. (Adv. Drug Deliv. Rev. 60:1421-1434 (2008)).
Rudnick et al. (Can. Biotherp. & Radiopharm. 24: 155-162 (2009)).
Lederman et al (Molecular Immunology 28:1171-1181, 1991).
Li et al (Proc. Natl. Acad. Sci. USA 77:3211-3214, 1980).
Cayabyab et al., 2000, “Apelin, the Natural Ligand of the Orphan Seven-Transmembrane Receptor APJ, Inhibits Human Immunodeficiency Virus Type 1 Entry,”Journal of Virology, 7(24):11972-11976.
Devic et al., 1999, “Amino acid sequence and embryonic expression ofmsr/apj, the mouse homolog of Xenopus X-msr and human APJ,”Mechanisms of Development, 84:199-203.
Devic et al., 1999, “Expression of Endothelial Precursors of a New Family of Receptors Sharing Similarities with CXC Chemokine Receptors,”Pathologie Biologie47(4):330-338.
Eyetech Study Group, 2003, “Anti-Vascular Endothelial Growth Factor Therapy for Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration,”Ophthalmology, 2003, 110(5):979-86.
Hosoya et al., 2000, “Molecular and Functional Characteristics of APJ,”The Journal of Biological Chemistry, 275(28):21061-21067.
Katugampola et al., 2001, “[125I]-(Pyr1)Apelin-13 is a novel radioligand for localizing the APJ orphan receptor in human and rat tissues with evidence for a vasoconstrictor role in man,”British Journal of Pharmacology, 132:1255-1260.
Saint-Geniez et al., 2002, “Expression of the murinemsr/apjreceptor and its ligand apelin is upregulated during formation of the retinal vessels,”Mechanisms of Development, 110:183-186.
Kalin et al., 2007, “Paracrine and Autocrine Mechanisms of Apelin Signaling Govern Embryonic and Tumor Angiogenesis,” Developmental Biology, 305:599-614.
Kleinz et al., 2004, “Immunocytochemical Localization of the Endogenous Vasoactive Peptide Apelin to Human Vascular and Endocardial Endothelial Cells,” Regulatory Peptides, 118:119-125.
Levine et al., 2003, “Fluorescent Labeling of Endothelial Cells Allow in vivo, Continuous Characterization of the Vascular Development of Xenopus Laevis,” Developmental Biology, 254:50-67.
O'Dowd et al., 1993, “A Human Gene that Shows Identity with the Gene Encoding the Angiotensin Receptor is Located on Chromosome 11,” Gene, 136:355-360.
Sorli et al., 2007, “Apelin is a Potent Activator of Tumour Neoangiogenesis,” Oncogene (2007), 1-8.
Sorli et al., 2006, “Therapeutic Potential of Interfering with Apeling Signalling,” Drug Discovery Today, 11 (23/24):1100-1106.
Arizona Board of Regents on behalf of the University of Arizona
Bristol Lynn
Sutherland & Asbill & Brennan LLP
LandOfFree
Methods for modulating angiogenesis with apelin compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for modulating angiogenesis with apelin compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for modulating angiogenesis with apelin compositions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186008